13 Feb FDA APPROVES EISAI’S LENVIMA™ (LENVATINIB) FOR THE TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
New Therapy Demonstrated a Dramatic Improvement in Progression-Free Survival and a Statistically Significant Overall Response Rate in Some Patients with RAI-Refractory Differentiated Thyroid Cancer File Submission and Approval Based on Data from Phase 3 SELECT Study Published in New England Journal of Medicine on February 12,...